FDC gains on receiving USFDA’s approval for Dorzolamide and Timolol Ophthalmic Solution

17 Jun 2019 Evaluate

FDC is currently trading at Rs. 174.50, up by 1.30 points or 0.75% from its previous closing of Rs. 173.20 on the BSE.

The scrip opened at Rs. 173.20 and has touched a high and low of Rs. 176.90 and Rs. 173.20 respectively. So far 1466 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 269.40 on 01-Aug-2018 and a 52 week low of Rs. 148.20 on 19-Feb-2019.

Last one week high and low of the scrip stood at Rs. 185.80 and Rs. 171.20 respectively. The current market cap of the company is Rs. 3020.66 crore.

The promoters holding in the company stood at 69.07%, while Institutions and Non-Institutions held 14.11% and 16.82% respectively.

FDC has been granted ANDA approval by United States Food and Drug Administration (USFDA), for Dorzolamide and Timolol Ophthalmic Solution USP 22.3mg/6.83mg per ml, a generic version of Cosopt of Oak Pharmaceuticals Inc.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

FDC Share Price

407.45 -3.00 (-0.73%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×